Nomenclature
CAS number: 68-22-4
(17α)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one; 19-nor-17α-ethynyltestosterone; 17α-ethynyl-19-nortestosterone; 19-nor-17α-ethynyl-17β-hydroxy-4-androsten-3-one; 19-nor-17α-ethynylandrosten-17β-ol-3-one; anhydrohydroxynorprogesterone; 19-norethisterone; norpregneninolone; “mini-pill”; Camila (Barr); Conludag (Searle); Menzol (Schwarz); Micronor (Ortho); Micronovum (Janssen-Cilag); Mini-Pe (Searle); Norcolut (Gedeon Richter); Noriday (Searle); Primolut N (Schering AG); Utovlan (Searle).
C
20H
26O
2; mol wt 298.42.
C 80.50%, H 8.78%, O 10.72%.
Description and references
Prepn from 19-nor-4-androstene-3,17-dione:
Djerassi et al., J. Am. Chem.
Soc. 76, 4092 (1954); US 2744122 (1956 to Syntex); De
Ruggieri, US 2849462 (1958). Pharmacokinetics:
H. Singh et al., Am. J. Obstet.
Gynecol. 135, 409 (1979); M. Humpel, Contraception 26, 83 (1982).
Double-blind, comparative clinical trial: S. Koetsawang et al., ibid. 25, 231 (1982);
A. Sheth et al., ibid. 243. Multicenter trial
of combination with ethinyl estradiol: M. Toews et al., Curr. Ther. Res. 41, 509 (1987). Review of carcinogenicity studies: IARC Monographs 21, 441-460 (1979).
Comprehensive description: A. P. Schroff, E. S. Moyer, Anal. Profiles Drug Subs. 4, 268-293
(1975).
Properties
Crystals from ethyl acetate, mp 203-204°. [α]D20 -31.7° (chloroform). First reported as [α]D20 -25° (chloroform). uv max (ethanol): 240 nm (log ε 4.24).Derivative
Mixture with ethinyl estradiol.
Nomenclature
Binovum (Ortho-Cilag); Brevicon (Watson); Estrostep (Warner-Lambert); Modicon (Ortho); Neocon 1/35 (Ortho-Cilag); Norimin (Searle); Norinyl 1+35 (Watson); Ortho-Novum (Ortho); Ovcon (Warner-Chilcott); Ovysmen (Janssen-Cilag); Tri-Norinyl (Watson); Trinovum (Janssen-Cilag). Derivative
Mixture with mestranol.
Nomenclature
Norinyl-1+50 (Watson); Ortho-Novin 1/50 (Ortho-Cilag); Ortho-Novum 1/50 (Ortho). Derivative
Acetate.
Nomenclature
CAS number: 51-98-9
Aygestin (Barr); Milligynon (Schering AG); Norlutate (Warner-Lambert); Primolut-Nor (Schering AG).
C
22H
28O
3; mol wt 340.46.
C 77.61%, H 8.29%, O 14.10%.
Description and references
Prepn: O. Engelfried et al., US 2964537 (1960 to Schering AG).
Properties
Crystals from methylene chloride + hexane, mp 161-162°. uv max: 240 nm
(ε 18690).Derivative
Acetate, mixture with ethinyl estradiol.
Nomenclature
Etalontin (Parke-Davis); Primosiston (Schering AG); Anovlar (Schering AG); Gynovlar (Schering AG); Loestrin (Warner-Lambert); Minovlar (Schering AG); Norlestrin (Warner-Lambert). Derivative
Enanthate.
Nomenclature
Noristerat (Schering AG). C
27H
38O
3; mol wt 410.59.
C 78.98%, H 9.33%, O 11.69%.
Description and references
Clinical trial as injectable contraceptive:
S. K. Banerjee et al., Contraception 30, 561 (1984).
Caution
Norethindrone is reasonably anticipated
to be a human carcinogen: Report on Carcinogens,
Eleventh Edition (PB2005-104914, 2004) p III-208.Therapeutic Category
Progestogen. Norethindrone and acetate in combination
with estrogen as contraceptive (oral). Enanthate as contraceptive
(injectable).
Keywords
Contraceptive (Injectable); Contraceptive (Oral); Progestogen